Mortality Advantage With Pimavanserin in Parkinson's Psychosis?
Use of pimavanserin was associated with 35% lower mortality for patients with Parkinson's disease–related psychosis compared with atypical antipsychotics, a large new real-world analysis shows.
Medscape Medical News
source https://www.medscape.com/viewarticle/977263?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/977263?src=rss
Comments
Post a Comment